Uploaded January 2023 | Updated November 2026, 7 hours ago
Novartis is transforming into a ‘pure-play’ Innovative Medicines company.
The Company will be a focused on five core therapeutic areas (Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology).
In a recent Meet Novartis Management Investor Relations session, Marie-France Tschudin President, Innovative Medicines International & Chief Commercial Officer at Novartis discusses how cardiovascular disease (CVD) needs to be approached differently for the future.
Meet Novartis Management
Event Date: September 22, 2022
Investors Page: bit.ly/3iPbZTF
Link to Novartis Strategy: bit.ly/3wiCJyW
Disclaimer: Meet Novartis Management event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3GW69rn
Follow @Novartis on Twitter: twitter.com/Novartis
Follow Novartis on LinkedIn: linkedin.com/company/novartis
Novartis is transforming into a ‘pure-play’ Innovative Medicines company.
The Company will be a focused on five core therapeutic areas (Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology).
In a recent Meet Novartis Management Investor Relations session, Marie-France Tschudin President, Innovative Medicines International & Chief Commercial Officer at Novartis discusses how cardiovascular disease (CVD) needs to be approached differently for the future.
Meet Novartis Management
Event Date: September 22, 2022
Investors Page: bit.ly/3iPbZTF
Link to Novartis Strategy: bit.ly/3wiCJyW
Disclaimer: Meet Novartis Management event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3GW69rn
Follow @Novartis on Twitter: twitter.com/Novartis
Follow Novartis on LinkedIn: linkedin.com/company/novartis










